Format

Send to

Choose Destination
Expert Opin Biol Ther. 2015;15 Suppl 1:S5-8. doi: 10.1517/14712598.2015.1026322. Epub 2015 Mar 16.

Innovative medicines: new regulatory procedures for the third millennium.

Author information

1
European Medicines Agency (EMA) , London , UK Guidorasi@hotmail.com.

Abstract

Despite tremendous progress in science and increasing investment in research and development, patients' access to innovative medicines remains limited. This is in part due to increasing regulatory requirements for product authorisation and cost-constrained national health systems. At the European Medicines Agency (EMA), we have tried to address these constraints by adapting our organisation and activities to changing business models, new technologies, and the current and emerging health needs in Europe. The main EMA initiatives to provide patients with effective, safe and affordable medicines are reviewed.

KEYWORDS:

European Medicines Agency; adaptive licensing; clinical trials; health technology assessment; innovative medicines; transparency

PMID:
25777774
DOI:
10.1517/14712598.2015.1026322
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center